Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyDiphenhydramine
Identification
- Name
- Diphenhydramine
- Accession Number
- DB01075 (APRD00587, DB06975)
- Type
- Small Molecule
- Groups
- Approved, Investigational
- Description
A histamine H1 antagonist used as an antiemetic, antitussive, for dermatoses and pruritus, for hypersensitivity reactions, as a hypnotic, an antiparkinson, and as an ingredient in common cold preparations. It has some undesired antimuscarinic and sedative effects.
- Structure
Structure for DB01075 (Diphenhydramine)
- Synonyms
- 2-(Benzhydryloxy)-N,N-dimethylethylamine
- 2-diphenylmethoxy-N,N-demthylethanamine
- alpha-(2-Dimethylaminoethoxy)diphenylmethane
- beta-Dimethylaminoethanol diphenylmethyl ether
- beta-Dimethylaminoethyl benzhydryl ether
- Difenhidramina
- Diphenhydraminum
- N-(2-(Diphenylmethoxy)ethyl)-N,N-dimethylamine
- O-benzhydryldimethylaminoethanol
- β-dimethylaminoethyl benzhydryl ether
- Product Ingredients
Ingredient UNII CAS InChI Key Diphenhydramine citrate 4OD433S209 88637-37-0 SPCKHVPPRJWQRZ-UHFFFAOYSA-N Diphenhydramine hydrochloride TC2D6JAD40 147-24-0 PCHPORCSPXIHLZ-UHFFFAOYSA-N Diphenhydramine methylbromide UJO67AO8YI 31065-89-1 BDQPXVWYFLTETB-UHFFFAOYSA-M Diphenhydramine salicylate 707L3YC54L 7491-10-3 RTSZUSOHOIFYSY-UHFFFAOYSA-N - Product Images
- Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Benadryl Inj. 50mg/ml Liquid 50 mg Intramuscular; Intravenous Warner Lambert Canada Inc. 1994-12-31 2000-11-27 Canada 
Diphenhydramine HCl Inj USP 50mg/ml Liquid 50 mg Intravenous International Medication Systems, Limited 1974-12-31 1997-08-15 Canada Diphenhydramine HCl Injection, USP Solution 50 mg Intramuscular; Intravenous Sterimax Inc 1994-12-31 Not applicable Canada Diphenhydramine Hydrochloride Injection Solution 50 mg Intramuscular; Intravenous Fresenius Kabi 2012-02-17 Not applicable Canada Diphenhydramine Hydrochloride Injection USP Liquid 50 mg Intramuscular; Intravenous Sandoz Canada Incorporated 1983-12-31 Not applicable Canada Diphenist 50mg/ml Liquid 50 mg Intramuscular; Intravenous Omega Laboratories Ltd 1997-10-28 Not applicable Canada Scheinpharm Diphenhydramine Inj.50mg/ml Solution 50 mg Intramuscular; Intravenous Schein Pharmaceutical Canada Inc. 1996-09-30 2004-07-26 Canada - Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Diphendydramine Hydrochloride Capsule 25 mg/1 Oral Remedy Repack 2010-12-17 2017-06-20 US 
Diphenhydramine Injection, solution 50 mg/mL Intravenous Remedy Repack 2013-06-13 2017-01-24 US Diphenhydramine Injection, solution 50 mg/mL Intramuscular; Intravenous Fresenius Kabi 2002-08-01 2018-01-31 US Diphenhydramine Hydrochloride Injection 50 mg/mL Intramuscular; Intravenous West Ward Pharmaceutical 1972-11-27 Not applicable US Diphenhydramine Hydrochloride Elixir 25 mg/10mL Oral Cardinal Health 1982-02-10 Not applicable US Diphenhydramine Hydrochloride Injection 50 mg/mL Intramuscular; Intravenous Sina Health Inc 1972-11-27 Not applicable US Diphenhydramine Hydrochloride Injection, solution 50 mg/mL Intramuscular; Intravenous General Injectables & Vaccines 2017-06-13 Not applicable US Diphenhydramine Hydrochloride Injection 50 mg/mL Intramuscular; Intravenous Rebel Distributors 1972-11-27 Not applicable US Diphenhydramine Hydrochloride Injection 50 mg/mL Intramuscular Remedy Repack 2013-06-10 2017-12-08 US Diphenhydramine Hydrochloride Injection 50 mg/mL Intramuscular; Intravenous Dispensing Solutions, Inc. 1972-11-27 Not applicable US - Over the Counter Products
Name Dosage Strength Route Labeller Marketing Start Marketing End 7 Select Allergy Tablet 25 mg/1 Oral 7 Eleven 2014-04-22 Not applicable US 7 Select Allergy Childrens Solution 12.5 mg/5mL Oral 7 Eleven 2014-08-05 Not applicable US 7 Select Night Time Sleep Aid Solution 50 mg/30mL Oral 7 Eleven 2014-04-22 Not applicable US Adult Allergy Solution 50 mg/20mL Oral Chain Drug Consortium 2015-05-04 Not applicable US Adult Allergy Relief Solution 50 mg/20mL Oral Walmart Stores 2017-05-03 Not applicable US After Bite Outdoor Gel 20 mg/mL Topical Tender Corporation 2016-11-01 2018-03-08 US After Bite Outdoor Gel 20 mg/g Topical Tender Corporation 2018-03-01 Not applicable US After Bite Plus Gel 20 mg/g Topical Tender Corporation 2018-03-01 Not applicable US After Bite Plus Cream 20 mg/mL Topical Tender Corporation 2012-07-03 2018-03-08 US After Bite Xtra Gel 20 mg/mL Topical Tender Corporation 2016-11-01 2018-03-08 US - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End 7 Select Ibuprofen PM Diphenhydramine citrate (38 mg/1) + Ibuprofen (200 mg/1) Tablet, film coated Oral 7 Eleven 2014-08-05 Not applicable US 7 Select Night Time Severe Cold Cough and Flu Diphenhydramine hydrochloride (25 mg/1) + Acetaminophen (650 mg/1) + Phenylephrine hydrochloride (10 mg/1) Powder, for solution Oral 7 Eleven 2016-01-25 Not applicable US 7 Select Night Time severe cold, cough and flu Diphenhydramine hydrochloride (25 mg/1) + Acetaminophen (650 mg/1) + Phenylephrine hydrochloride (10 mg/1) Powder, for solution Oral 7 Eleven 2015-11-12 2018-03-29 US 7 Select Pain Relief PM Diphenhydramine hydrochloride (25 mg/1) + Acetaminophen (500 mg/1) Tablet, film coated Oral 7 Eleven 2014-09-04 2017-11-22 US 7-Select Advil PM Diphenhydramine citrate (38 mg/1) + Ibuprofen (200 mg/1) Tablet, coated Oral Lil' Drug Store Products, Inc. 2011-06-01 2017-12-31 US Aceta-gesic Diphenhydramine hydrochloride (12.5 mg/1) + Acetaminophen (325 mg/1) Tablet, coated Oral Remedy Repack 2014-08-08 Not applicable US Aceta-gesic Diphenhydramine hydrochloride (12.5 mg/1) + Acetaminophen (325 mg/1) Tablet, coated Oral Rugby 2014-06-30 Not applicable US Acetadryl Diphenhydramine hydrochloride (25 mg/1) + Acetaminophen (500 mg/1) Tablet, film coated Oral Aidarex Pharmaceuticals LLC 2011-07-21 Not applicable US Acetadryl Diphenhydramine hydrochloride (25 mg/1) + Acetaminophen (500 mg/1) Tablet, film coated Oral Physicians Science & Nature Inc. 2011-07-21 2017-11-30 US Acetaminophen / Diphenhydramine 500/25 mg Diphenhydramine hydrochloride (25 mg/1) + Acetaminophen (500 mg/1) Tablet Oral Reliable 1 Laboratories 2015-11-01 Not applicable US - Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Airacof Diphenhydramine hydrochloride (12.5 mg/5mL) + Codeine phosphate (7.5 mg/5mL) + Phenylephrine hydrochloride (7.5 mg/5mL) Liquid Oral Centurion Labs 2010-01-08 2016-10-13 US Antiphlamine Coin Plaster Diphenhydramine (.246 mg/.2832g) + Camphor (1.108 mg/.2832g) + Menthol (2.769 mg/.2832g) Patch Topical Hanul Trading Co., Ltd. 2016-10-10 2017-02-11 US Contrast Allergy PreMed Pack Diphenhydramine + Prednisone Kit Shertech Laboratories, Llc 2016-09-13 Not applicable US Dicopanol Diphenhydramine hydrochloride Kit Oral California Pharmaceuticals, Llc 2016-01-01 Not applicable US Dicopanol Diphenhydramine hydrochloride Kit Oral Fusion Pharmaceuticals LLC 2010-02-08 Not applicable US Diphenhydramine HCl Diphenhydramine hydrochloride (25 mg/1) Capsule Oral Cardinal Health 2011-06-03 2017-07-18 US Diphenhydramine HCl Diphenhydramine hydrochloride (25 mg/1) Tablet Oral Cardinal Health 2011-06-03 Not applicable US FIRST Dukes Mouthwash Compounding Diphenhydramine hydrochloride + Hydrocortisone + Nystatin Kit Oral Cutis Pharma, Inc. 2010-12-15 2017-10-04 US FIRST Marys Mouthwash Compounding Diphenhydramine hydrochloride + Hydrocortisone + Nystatin + Tetracycline hydrochloride Kit Oral Cutis Pharma, Inc. 2010-12-15 2017-10-04 US Pain Relief PM Diphenhydramine hydrochloride (25 mg/1) + Acetaminophen (500 mg/1) Tablet, coated Oral Avema Pharma Solutions 2010-01-02 Not applicable US - International/Other Brands
- Aleryl / Alledryl / Allerdryl (Valeant) / Baramine / Beldin / Belix / Benylan (Biogen) / Dermodrin (Montavit) / Desentol (Meda) / Dibondrin (Montavit) / Dimedrol (Zdorovie) / Diphen (Wockhardt) / Dormarex 2 / Genahist / Histaxin (Meda) / Hyrexin (Hyrex) / Nytol Quickgels (GlaxoSmithKline) / Restamin (Kowa Souyaku) / Siladryl / Silphen Cough
- Categories
- Amines
- Aminoalkyl Ethers
- Anesthetics
- Anesthetics, Local
- Anti-Allergic Agents
- Antiemetics
- Antihistamines for Systemic Use
- Autonomic Agents
- Benzene Derivatives
- Benzhydryl Compounds
- Central Nervous System Agents
- Central Nervous System Depressants
- Cytochrome P-450 CYP1A2 Substrates
- Cytochrome P-450 CYP2B6 Substrates
- Cytochrome P-450 CYP2C19 Substrates
- Cytochrome P-450 CYP2C9 Substrates
- Cytochrome P-450 CYP2D6 Inhibitors
- Cytochrome P-450 CYP2D6 Inhibitors (moderate)
- Cytochrome P-450 CYP2D6 Substrates
- Cytochrome P-450 Enzyme Inhibitors
- Ethanolamine Derivatives
- Ethylamines
- First Generation Antihistamines
- Gastrointestinal Agents
- Histamine Agents
- Histamine Antagonists
- Histamine H1 Antagonists
- Histamine-1 Receptor Antagonist
- Hypnotics and Sedatives
- Neurotransmitter Agents
- Peripheral Nervous System Agents
- QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying)
- Sensory System Agents
- Sleep Aids, Pharmaceutical
- UNII
- 8GTS82S83M
- CAS number
- 58-73-1
- Weight
- Average: 255.3547
Monoisotopic: 255.162314299 - Chemical Formula
- C17H21NO
- InChI Key
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N
- InChI
- InChI=1S/C17H21NO/c1-18(2)13-14-19-17(15-9-5-3-6-10-15)16-11-7-4-8-12-16/h3-12,17H,13-14H2,1-2H3
- IUPAC Name
- [2-(diphenylmethoxy)ethyl]dimethylamine
- SMILES
- CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1
Pharmacology
- Indication
For the treatment of symptoms associated with Vertigo/Meniere's disease, nausea and vomiting, motion sickness and insect bite.
- Structured Indications
- Pharmacodynamics
Diphenhydramine is an antihistamine of the ethanolamine class. Ethanolamine antihistamines have significant antimuscarinic activity and produce marked sedation in most patients. In addition to the usual allergic symptoms, the drug also treats irritant cough and nausea, vomiting, and vertigo associated with motion sickness. It also is used commonly to treat drug-induced extrapyramidal symptoms as well as to treat mild cases of Parkinson's disease. Rather than preventing the release of histamine, as do cromolyn and nedocromil, diphenhydramine competes with free histamine for binding at HA-receptor sites. Diphenhydramine competitively antagonizes the effects of histamine on HA-receptors in the GI tract, uterus, large blood vessels, and bronchial muscle. Ethanolamine derivatives have greater anticholinergic activity than do other antihistamines, which probably accounts for the antidyskinetic action of diphenhydramine. This anticholinergic action appears to be due to a central antimuscarinic effect, which also may be responsible for its antiemetic effects, although the exact mechanism is unknown.
- Mechanism of action
Diphenhydramine competes with free histamine for binding at HA-receptor sites. This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding.
Target Actions Organism AHistamine H1 receptor antagonistHuman UMuscarinic acetylcholine receptor M2 antagonistHuman - Absorption
Quickly absorbed with maximum activity occurring in approximately one hour.
- Volume of distribution
- Not Available
- Protein binding
98 to 99%
- Metabolism
Hepatic and renal
- Route of elimination
Little, if any, is excreted unchanged in the urine; most appears as the degradation products of metabolic transformation in the liver, which are almost completely excreted within 24 hours.
- Half life
1-4 hours
- Clearance
- Not Available
- Toxicity
LD50=500 mg/kg (orally in rats). Considerable overdosage can lead to myocardial infarction (heart attack), serious ventricular dysrhythmias, coma and death.
- Affected organisms
- Humans and other mammals
- Pathways
Pathway Category Diphenhydramine H1-Antihistamine Action Drug action - Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group 2,5-Dimethoxy-4-ethylamphetamine 2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Diphenhydramine. Experimental, Illicit 2,5-Dimethoxy-4-ethylthioamphetamine 2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Diphenhydramine. Experimental 3,4-Methylenedioxyamphetamine 3,4-Methylenedioxyamphetamine may decrease the sedative activities of Diphenhydramine. Experimental, Illicit 4-Bromo-2,5-dimethoxyamphetamine 4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Diphenhydramine. Experimental, Illicit 4-Methoxyamphetamine The metabolism of 4-Methoxyamphetamine can be decreased when combined with Diphenhydramine. Experimental, Illicit 7-Nitroindazole The risk or severity of adverse effects can be increased when Diphenhydramine is combined with 7-Nitroindazole. Experimental Abiraterone The serum concentration of Diphenhydramine can be increased when it is combined with Abiraterone. Approved Acepromazine The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Acepromazine. Approved, Vet Approved Aceprometazine The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Aceprometazine. Approved Acetaminophen The metabolism of Acetaminophen can be decreased when combined with Diphenhydramine. Approved Acetylcholine The metabolism of Acetylcholine can be decreased when combined with Diphenhydramine. Approved Adipiplon The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Adipiplon. Investigational Agomelatine The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Agomelatine. Approved, Investigational Ajmaline The metabolism of Ajmaline can be decreased when combined with Diphenhydramine. Approved, Investigational Alaproclate The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Alaproclate. Experimental Alfaxalone The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Alfaxalone. Vet Approved Alfentanil The risk or severity of adverse effects can be increased when Alfentanil is combined with Diphenhydramine. Approved, Illicit Allopregnanolone The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Allopregnanolone. Investigational Almotriptan The metabolism of Almotriptan can be decreased when combined with Diphenhydramine. Approved, Investigational Alogliptin The metabolism of Alogliptin can be decreased when combined with Diphenhydramine. Approved Alphacetylmethadol The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Alphacetylmethadol. Experimental, Illicit Alphaprodine The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Alphaprodine. Illicit Alprazolam The risk or severity of adverse effects can be increased when Alprazolam is combined with Diphenhydramine. Approved, Illicit, Investigational Alprenolol The metabolism of Alprenolol can be decreased when combined with Diphenhydramine. Approved, Withdrawn Aminophenazone The metabolism of Aminophenazone can be decreased when combined with Diphenhydramine. Approved, Withdrawn Amiodarone The metabolism of Diphenhydramine can be decreased when combined with Amiodarone. Approved, Investigational Amisulpride The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Amisulpride. Approved, Investigational Amitriptyline The metabolism of Amitriptyline can be decreased when combined with Diphenhydramine. Approved Amobarbital The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Amobarbital. Approved, Illicit Amoxapine The metabolism of Amoxapine can be decreased when combined with Diphenhydramine. Approved Amperozide The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Amperozide. Experimental Amphetamine The metabolism of Amphetamine can be decreased when combined with Diphenhydramine. Approved, Illicit, Investigational Amprenavir The metabolism of Amprenavir can be decreased when combined with Diphenhydramine. Approved, Investigational Amsacrine The metabolism of Amsacrine can be decreased when combined with Diphenhydramine. Approved, Investigational Anagrelide Diphenhydramine may increase the QTc-prolonging activities of Anagrelide. Approved Antipyrine The metabolism of Antipyrine can be decreased when combined with Diphenhydramine. Approved, Investigational Apalutamide The serum concentration of Diphenhydramine can be decreased when it is combined with Apalutamide. Approved, Investigational Aprepitant The metabolism of Diphenhydramine can be increased when combined with Aprepitant. Approved, Investigational Aprindine The metabolism of Aprindine can be decreased when combined with Diphenhydramine. Approved Arformoterol The metabolism of Arformoterol can be decreased when combined with Diphenhydramine. Approved, Investigational Aripiprazole The serum concentration of Aripiprazole can be increased when it is combined with Diphenhydramine. Approved, Investigational Armodafinil The metabolism of Diphenhydramine can be decreased when combined with Armodafinil. Approved, Investigational Arsenic trioxide Diphenhydramine may increase the QTc-prolonging activities of Arsenic trioxide. Approved, Investigational Artemether Diphenhydramine may increase the QTc-prolonging activities of Artemether. Approved Articaine The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Articaine. Approved Asenapine Diphenhydramine may increase the QTc-prolonging activities of Asenapine. Approved Astemizole The metabolism of Astemizole can be decreased when combined with Diphenhydramine. Approved, Withdrawn Asunaprevir The metabolism of Asunaprevir can be decreased when combined with Diphenhydramine. Approved, Investigational, Withdrawn Atomoxetine The metabolism of Diphenhydramine can be decreased when combined with Atomoxetine. Approved Azaperone The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Azaperone. Investigational, Vet Approved Azelastine Diphenhydramine may increase the central nervous system depressant (CNS depressant) activities of Azelastine. Approved Azithromycin The metabolism of Diphenhydramine can be decreased when combined with Azithromycin. Approved Baclofen The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Baclofen. Approved Barbital The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Barbital. Illicit Bedaquiline Diphenhydramine may increase the QTc-prolonging activities of Bedaquiline. Approved Benperidol The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Benperidol. Approved, Investigational Benzatropine The metabolism of Benzatropine can be decreased when combined with Diphenhydramine. Approved Benzocaine The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Benzocaine. Approved, Investigational Benzphetamine Benzphetamine may decrease the sedative activities of Diphenhydramine. Approved, Illicit Benzyl alcohol The metabolism of Benzyl alcohol can be decreased when combined with Diphenhydramine. Approved Benzylpenicilloyl Polylysine Diphenhydramine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent. Approved Bepridil The metabolism of Bepridil can be decreased when combined with Diphenhydramine. Approved, Withdrawn Betahistine The therapeutic efficacy of Betahistine can be decreased when used in combination with Diphenhydramine. Approved, Investigational Betaxolol The metabolism of Betaxolol can be decreased when combined with Diphenhydramine. Approved, Investigational Bisoprolol The metabolism of Bisoprolol can be decreased when combined with Diphenhydramine. Approved Bortezomib The metabolism of Diphenhydramine can be decreased when combined with Bortezomib. Approved, Investigational Brexpiprazole The serum concentration of Brexpiprazole can be increased when it is combined with Diphenhydramine. Approved, Investigational Brimonidine Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Diphenhydramine. Approved Bromazepam The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Bromazepam. Approved, Illicit, Investigational Bromisoval The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Bromisoval. Experimental Bromperidol The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Bromperidol. Approved, Investigational Brompheniramine The metabolism of Brompheniramine can be decreased when combined with Diphenhydramine. Approved Brotizolam The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Brotizolam. Approved, Investigational, Withdrawn Bufuralol The metabolism of Bufuralol can be decreased when combined with Diphenhydramine. Experimental, Investigational Bupivacaine The metabolism of Bupivacaine can be decreased when combined with Diphenhydramine. Approved, Investigational Buprenorphine Diphenhydramine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Approved, Illicit, Investigational, Vet Approved Bupropion The metabolism of Diphenhydramine can be decreased when combined with Bupropion. Approved Buspirone The metabolism of Buspirone can be decreased when combined with Diphenhydramine. Approved, Investigational Butabarbital The risk or severity of adverse effects can be increased when Butabarbital is combined with Diphenhydramine. Approved, Illicit Butacaine The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Butacaine. Vet Approved Butalbital The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Butalbital. Approved, Illicit Butamben The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Butamben. Approved, Withdrawn Butethal The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Butethal. Approved, Illicit Butorphanol The risk or severity of adverse effects can be increased when Butorphanol is combined with Diphenhydramine. Approved, Illicit, Vet Approved Caffeine The metabolism of Diphenhydramine can be decreased when combined with Caffeine. Approved Canertinib The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Canertinib. Investigational Capecitabine The metabolism of Diphenhydramine can be decreased when combined with Capecitabine. Approved, Investigational Captopril The metabolism of Captopril can be decreased when combined with Diphenhydramine. Approved Carbamazepine The metabolism of Diphenhydramine can be increased when combined with Carbamazepine. Approved, Investigational Carbinoxamine The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Carbinoxamine. Approved Carfentanil The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Carfentanil. Illicit, Investigational, Vet Approved Cariprazine The metabolism of Cariprazine can be decreased when combined with Diphenhydramine. Approved, Investigational Carisoprodol The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Carisoprodol. Approved Carteolol The metabolism of Carteolol can be decreased when combined with Diphenhydramine. Approved Carvedilol The metabolism of Carvedilol can be decreased when combined with Diphenhydramine. Approved, Investigational Celecoxib The metabolism of Diphenhydramine can be decreased when combined with Celecoxib. Approved, Investigational Cephalexin The metabolism of Cephalexin can be decreased when combined with Diphenhydramine. Approved, Investigational, Vet Approved Ceritinib The serum concentration of Diphenhydramine can be increased when it is combined with Ceritinib. Approved Cetirizine The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Cetirizine. Approved Cevimeline The metabolism of Cevimeline can be decreased when combined with Diphenhydramine. Approved Chloral hydrate The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Chloral hydrate. Approved, Illicit, Investigational, Vet Approved Chloramphenicol The metabolism of Diphenhydramine can be decreased when combined with Chloramphenicol. Approved, Vet Approved Chlordiazepoxide The metabolism of Chlordiazepoxide can be decreased when combined with Diphenhydramine. Approved, Illicit, Investigational Chlormezanone The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Chlormezanone. Approved, Investigational, Withdrawn Chloroprocaine The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Chloroprocaine. Approved Chloroquine The metabolism of Chloroquine can be decreased when combined with Diphenhydramine. Approved, Investigational, Vet Approved Chlorphenamine The metabolism of Chlorphenamine can be decreased when combined with Diphenhydramine. Approved Chlorphentermine Chlorphentermine may decrease the sedative activities of Diphenhydramine. Illicit, Withdrawn Chlorpromazine The metabolism of Diphenhydramine can be decreased when combined with Chlorpromazine. Approved, Investigational, Vet Approved Chlorprothixene The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Chlorprothixene. Approved, Investigational, Withdrawn Chlorzoxazone The metabolism of Chlorzoxazone can be decreased when combined with Diphenhydramine. Approved Cholecalciferol The metabolism of Diphenhydramine can be decreased when combined with Cholecalciferol. Approved, Nutraceutical Cilostazol The metabolism of Cilostazol can be decreased when combined with Diphenhydramine. Approved, Investigational Cimetidine The metabolism of Diphenhydramine can be decreased when combined with Cimetidine. Approved, Investigational Cinacalcet The metabolism of Diphenhydramine can be decreased when combined with Cinacalcet. Approved Cinchocaine The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Cinchocaine. Approved, Vet Approved Cinnarizine The metabolism of Cinnarizine can be decreased when combined with Diphenhydramine. Approved, Investigational Ciprofloxacin Diphenhydramine may increase the QTc-prolonging activities of Ciprofloxacin. Approved, Investigational Cisapride Diphenhydramine may increase the QTc-prolonging activities of Cisapride. Approved, Investigational, Withdrawn Citalopram Diphenhydramine may increase the QTc-prolonging activities of Citalopram. Approved Clarithromycin Diphenhydramine may increase the QTc-prolonging activities of Clarithromycin. Approved Clemastine The metabolism of Diphenhydramine can be decreased when combined with Clemastine. Approved, Investigational Clevidipine The metabolism of Clevidipine can be decreased when combined with Diphenhydramine. Approved, Investigational Clidinium The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Clidinium. Approved Clobazam The metabolism of Diphenhydramine can be decreased when combined with Clobazam. Approved, Illicit clomethiazole The risk or severity of adverse effects can be increased when Diphenhydramine is combined with clomethiazole. Investigational Clomipramine The metabolism of Diphenhydramine can be decreased when combined with Clomipramine. Approved, Investigational, Vet Approved Clonazepam The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Clonazepam. Approved, Illicit Clonidine The metabolism of Clonidine can be decreased when combined with Diphenhydramine. Approved Clopenthixol The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Clopenthixol. Experimental Clopidogrel The metabolism of Diphenhydramine can be decreased when combined with Clopidogrel. Approved Clorazepate The risk or severity of adverse effects can be increased when Clorazepate is combined with Diphenhydramine. Approved, Illicit Clothiapine The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Clothiapine. Experimental Clotrimazole The metabolism of Diphenhydramine can be decreased when combined with Clotrimazole. Approved, Vet Approved Clozapine The metabolism of Clozapine can be decreased when combined with Diphenhydramine. Approved Cobicistat The serum concentration of Diphenhydramine can be increased when it is combined with Cobicistat. Approved Cocaine The metabolism of Diphenhydramine can be decreased when combined with Cocaine. Approved, Illicit Codeine The therapeutic efficacy of Codeine can be decreased when used in combination with Diphenhydramine. Approved, Illicit Crisaborole The metabolism of Diphenhydramine can be decreased when combined with Crisaborole. Approved, Investigational Crizotinib The metabolism of Diphenhydramine can be decreased when combined with Crizotinib. Approved Cyclizine The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Cyclizine. Approved Cyclobenzaprine The metabolism of Cyclobenzaprine can be decreased when combined with Diphenhydramine. Approved Cyclophosphamide The metabolism of Cyclophosphamide can be decreased when combined with Diphenhydramine. Approved, Investigational Cyclopropane The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Cyclopropane. Experimental Cyclosporine The metabolism of Diphenhydramine can be decreased when combined with Cyclosporine. Approved, Investigational, Vet Approved Cyproheptadine The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Cyproheptadine. Approved Cyproterone acetate The serum concentration of Diphenhydramine can be decreased when it is combined with Cyproterone acetate. Approved, Investigational Dabrafenib The serum concentration of Diphenhydramine can be decreased when it is combined with Dabrafenib. Approved, Investigational Dantrolene The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Dantrolene. Approved, Investigational Dapagliflozin The metabolism of Dapagliflozin can be decreased when combined with Diphenhydramine. Approved Dapiprazole The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Dapiprazole. Approved Dapoxetine The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Dapoxetine. Investigational Darifenacin The metabolism of Diphenhydramine can be decreased when combined with Darifenacin. Approved, Investigational Darunavir The serum concentration of Diphenhydramine can be increased when it is combined with Darunavir. Approved Dasabuvir The metabolism of Dasabuvir can be decreased when combined with Diphenhydramine. Approved Debrisoquin The metabolism of Debrisoquin can be decreased when combined with Diphenhydramine. Approved, Investigational Deferasirox The serum concentration of Diphenhydramine can be increased when it is combined with Deferasirox. Approved, Investigational Delavirdine The metabolism of Diphenhydramine can be decreased when combined with Delavirdine. Approved Deramciclane The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Deramciclane. Investigational Desflurane The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Desflurane. Approved Desipramine The metabolism of Diphenhydramine can be decreased when combined with Desipramine. Approved, Investigational Desloratadine The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Desloratadine. Approved, Investigational Desvenlafaxine The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Desvenlafaxine. Approved, Investigational Detomidine The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Detomidine. Vet Approved Deutetrabenazine The risk or severity of sedation and somnolence can be increased when Diphenhydramine is combined with Deutetrabenazine. Approved, Investigational Dexbrompheniramine The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Dexbrompheniramine. Approved Dexchlorpheniramine maleate The metabolism of Dexchlorpheniramine maleate can be decreased when combined with Diphenhydramine. Approved Dexfenfluramine The metabolism of Dexfenfluramine can be decreased when combined with Diphenhydramine. Approved, Illicit, Investigational, Withdrawn Dexmedetomidine The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Dexmedetomidine. Approved, Vet Approved Dexmethylphenidate The metabolism of Dexmethylphenidate can be decreased when combined with Diphenhydramine. Approved, Investigational Dextroamphetamine The metabolism of Dextroamphetamine can be decreased when combined with Diphenhydramine. Approved, Illicit Dextromethorphan The metabolism of Dextromethorphan can be decreased when combined with Diphenhydramine. Approved Dextromoramide The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Dextromoramide. Experimental, Illicit Dextropropoxyphene The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Dextropropoxyphene. Approved, Illicit, Investigational, Withdrawn Dezocine The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Dezocine. Approved, Investigational Diazepam The risk or severity of adverse effects can be increased when Diazepam is combined with Diphenhydramine. Approved, Illicit, Investigational, Vet Approved Diethyl ether The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Diethyl ether. Experimental Diethylpropion Diethylpropion may decrease the sedative activities of Diphenhydramine. Approved, Illicit Difenoxin The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Difenoxin. Approved, Illicit Dihydrocodeine The metabolism of Dihydrocodeine can be decreased when combined with Diphenhydramine. Approved, Illicit Dihydroetorphine The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Dihydroetorphine. Experimental, Illicit Dihydromorphine The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Dihydromorphine. Experimental, Illicit Diltiazem The metabolism of Diltiazem can be decreased when combined with Diphenhydramine. Approved, Investigational Dimenhydrinate The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Dimenhydrinate. Approved Diphenoxylate The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Diphenoxylate. Approved, Illicit Disopyramide Diphenhydramine may increase the QTc-prolonging activities of Disopyramide. Approved Dixyrazine The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Dixyrazine. Experimental Dofetilide Diphenhydramine may increase the QTc-prolonging activities of Dofetilide. Approved, Investigational Dolasetron The metabolism of Dolasetron can be decreased when combined with Diphenhydramine. Approved, Investigational Domperidone Diphenhydramine may increase the QTc-prolonging activities of Domperidone. Approved, Investigational, Vet Approved Donepezil The metabolism of Donepezil can be decreased when combined with Diphenhydramine. Approved Dopamine The metabolism of Dopamine can be decreased when combined with Diphenhydramine. Approved Doramectin The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Doramectin. Vet Approved Dosulepin The metabolism of Diphenhydramine can be decreased when combined with Dosulepin. Approved Doxazosin The metabolism of Doxazosin can be decreased when combined with Diphenhydramine. Approved Doxepin The metabolism of Doxepin can be decreased when combined with Diphenhydramine. Approved, Investigational Doxorubicin The serum concentration of Doxorubicin can be increased when it is combined with Diphenhydramine. Approved, Investigational Doxorubicin The metabolism of Doxorubicin can be decreased when combined with Diphenhydramine. Approved, Investigational Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Diphenhydramine. Approved, Vet Approved DPDPE The risk or severity of adverse effects can be increased when Diphenhydramine is combined with DPDPE. Experimental Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Diphenhydramine. Approved, Illicit Dronedarone Diphenhydramine may increase the QTc-prolonging activities of Dronedarone. Approved Droperidol Droperidol may increase the central nervous system depressant (CNS depressant) activities of Diphenhydramine. Approved, Vet Approved Drotebanol The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Drotebanol. Experimental, Illicit Duloxetine The metabolism of Diphenhydramine can be decreased when combined with Duloxetine. Approved Dyclonine The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Dyclonine. Approved Ecgonine The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Ecgonine. Experimental, Illicit Ecopipam The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Ecopipam. Investigational Efavirenz The metabolism of Diphenhydramine can be decreased when combined with Efavirenz. Approved, Investigational Eletriptan The metabolism of Eletriptan can be decreased when combined with Diphenhydramine. Approved, Investigational Eliglustat The serum concentration of Eliglustat can be increased when it is combined with Diphenhydramine. Approved Eltanolone The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Eltanolone. Investigational Enasidenib The metabolism of Enasidenib can be decreased when combined with Diphenhydramine. Approved, Investigational Encainide The metabolism of Encainide can be decreased when combined with Diphenhydramine. Approved, Investigational, Withdrawn Enclomiphene The metabolism of Enclomiphene can be decreased when combined with Diphenhydramine. Investigational Enflurane The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Enflurane. Approved, Investigational, Vet Approved Entacapone The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Entacapone. Approved, Investigational Epinastine The metabolism of Epinastine can be decreased when combined with Diphenhydramine. Approved, Investigational Erlotinib The metabolism of Erlotinib can be decreased when combined with Diphenhydramine. Approved, Investigational Erythromycin Diphenhydramine may increase the QTc-prolonging activities of Erythromycin. Approved, Investigational, Vet Approved Escitalopram Diphenhydramine may increase the QTc-prolonging activities of Escitalopram. Approved, Investigational Eslicarbazepine acetate The metabolism of Diphenhydramine can be decreased when combined with Eslicarbazepine acetate. Approved Esmirtazapine The metabolism of Esmirtazapine can be decreased when combined with Diphenhydramine. Investigational Esomeprazole The metabolism of Diphenhydramine can be decreased when combined with Esomeprazole. Approved, Investigational Estazolam The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Estazolam. Approved, Illicit Eszopiclone The risk or severity of adverse effects can be increased when Eszopiclone is combined with Diphenhydramine. Approved, Investigational Ethanol Diphenhydramine may increase the central nervous system depressant (CNS depressant) activities of Ethanol. Approved Ethchlorvynol The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Ethchlorvynol. Approved, Illicit, Withdrawn Ethosuximide The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Ethosuximide. Approved Ethotoin The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Ethotoin. Approved Ethyl carbamate The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Ethyl carbamate. Withdrawn Ethyl chloride The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Ethyl chloride. Approved, Experimental, Investigational Ethyl loflazepate The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Ethyl loflazepate. Approved, Illicit Ethylmorphine The metabolism of Ethylmorphine can be decreased when combined with Diphenhydramine. Approved, Illicit Etidocaine The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Etidocaine. Approved Etifoxine The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Etifoxine. Investigational, Withdrawn Etizolam The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Etizolam. Approved Etomidate The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Etomidate. Approved Etoperidone The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Etoperidone. Withdrawn Etoricoxib The metabolism of Etoricoxib can be decreased when combined with Diphenhydramine. Approved, Investigational Etorphine The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Etorphine. Illicit, Vet Approved Etravirine The metabolism of Diphenhydramine can be decreased when combined with Etravirine. Approved Ezogabine The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Ezogabine. Approved, Investigational Felbamate The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Felbamate. Approved Fencamfamine The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Fencamfamine. Approved, Illicit, Withdrawn Fentanyl The risk or severity of adverse effects can be increased when Fentanyl is combined with Diphenhydramine. Approved, Illicit, Investigational, Vet Approved Fesoterodine The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Diphenhydramine. Approved Fexofenadine The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Fexofenadine. Approved, Investigational Fingolimod The metabolism of Fingolimod can be decreased when combined with Diphenhydramine. Approved, Investigational Flecainide The metabolism of Flecainide can be decreased when combined with Diphenhydramine. Approved, Withdrawn Flibanserin The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Flibanserin. Approved, Investigational Floxuridine The metabolism of Diphenhydramine can be decreased when combined with Floxuridine. Approved Fluanisone The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Fluanisone. Experimental Fluconazole The metabolism of Diphenhydramine can be decreased when combined with Fluconazole. Approved, Investigational Fludiazepam The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Fludiazepam. Approved, Illicit Flunarizine The metabolism of Flunarizine can be decreased when combined with Diphenhydramine. Approved Flunitrazepam The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Flunitrazepam. Approved, Illicit Fluorouracil The metabolism of Diphenhydramine can be decreased when combined with Fluorouracil. Approved Fluoxetine The metabolism of Diphenhydramine can be decreased when combined with Fluoxetine. Approved, Vet Approved Flupentixol Diphenhydramine may increase the QTc-prolonging activities of Flupentixol. Approved, Investigational, Withdrawn Fluphenazine The metabolism of Fluphenazine can be decreased when combined with Diphenhydramine. Approved Flurazepam The risk or severity of adverse effects can be increased when Flurazepam is combined with Diphenhydramine. Approved, Illicit, Investigational Fluspirilene The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Fluspirilene. Approved, Investigational Fluticasone propionate The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Fluticasone propionate. Approved Fluvastatin The metabolism of Fluvastatin can be decreased when combined with Diphenhydramine. Approved Fluvoxamine The metabolism of Diphenhydramine can be decreased when combined with Fluvoxamine. Approved, Investigational Formoterol The metabolism of Formoterol can be decreased when combined with Diphenhydramine. Approved, Investigational Fosphenytoin The metabolism of Diphenhydramine can be increased when combined with Fosphenytoin. Approved, Investigational Fospropofol The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Fospropofol. Approved, Illicit, Investigational Gabapentin The risk or severity of adverse effects can be increased when Gabapentin is combined with Diphenhydramine. Approved, Investigational Gabapentin Enacarbil The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Gabapentin Enacarbil. Approved, Investigational Gadobenic acid Diphenhydramine may increase the QTc-prolonging activities of Gadobenic acid. Approved, Investigational Galantamine The metabolism of Galantamine can be decreased when combined with Diphenhydramine. Approved Gamma Hydroxybutyric Acid The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Gamma Hydroxybutyric Acid. Approved, Illicit, Investigational Gefitinib The metabolism of Gefitinib can be decreased when combined with Diphenhydramine. Approved, Investigational Gemfibrozil The metabolism of Diphenhydramine can be decreased when combined with Gemfibrozil. Approved Gemifloxacin Diphenhydramine may increase the QTc-prolonging activities of Gemifloxacin. Approved, Investigational Gepefrine Gepefrine may decrease the sedative activities of Diphenhydramine. Experimental Gepirone The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Gepirone. Investigational Glutethimide The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Glutethimide. Approved, Illicit Goserelin Diphenhydramine may increase the QTc-prolonging activities of Goserelin. Approved Granisetron The metabolism of Granisetron can be decreased when combined with Diphenhydramine. Approved, Investigational Guanfacine The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Guanfacine. Approved, Investigational Halazepam The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Halazepam. Approved, Illicit, Withdrawn Halofantrine The metabolism of Halofantrine can be decreased when combined with Diphenhydramine. Approved Haloperidol The metabolism of Diphenhydramine can be decreased when combined with Haloperidol. Approved Halothane The metabolism of Halothane can be decreased when combined with Diphenhydramine. Approved, Vet Approved Heroin The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Heroin. Approved, Illicit, Investigational Hexobarbital The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Hexobarbital. Approved Hyaluronidase The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Diphenhydramine. Approved, Investigational Hydrocodone Diphenhydramine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. Approved, Illicit Hydromorphone The metabolism of Hydromorphone can be decreased when combined with Diphenhydramine. Approved, Illicit Hydroxyamphetamine Hydroxyamphetamine may decrease the sedative activities of Diphenhydramine. Approved Hydroxyzine Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Diphenhydramine. Approved Ibrutinib The metabolism of Ibrutinib can be decreased when combined with Diphenhydramine. Approved Ibutilide Diphenhydramine may increase the QTc-prolonging activities of Ibutilide. Approved Idarubicin The metabolism of Idarubicin can be decreased when combined with Diphenhydramine. Approved Iloperidone Diphenhydramine may increase the QTc-prolonging activities of Iloperidone. Approved Imatinib The metabolism of Imatinib can be decreased when combined with Diphenhydramine. Approved Imipramine The metabolism of Imipramine can be decreased when combined with Diphenhydramine. Approved Indalpine The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Indalpine. Investigational, Withdrawn Indinavir The metabolism of Diphenhydramine can be decreased when combined with Indinavir. Approved Indiplon The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Indiplon. Investigational Iofetamine I-123 Iofetamine I-123 may decrease the sedative activities of Diphenhydramine. Approved Ipratropium bromide The metabolism of Ipratropium bromide can be decreased when combined with Diphenhydramine. Approved Irbesartan The metabolism of Diphenhydramine can be decreased when combined with Irbesartan. Approved, Investigational Isavuconazole The serum concentration of Diphenhydramine can be decreased when it is combined with Isavuconazole. Approved, Investigational Isoflurane The risk or severity of adverse effects can be increased when Isoflurane is combined with Diphenhydramine. Approved, Vet Approved Isoniazid The metabolism of Diphenhydramine can be decreased when combined with Isoniazid. Approved, Investigational Ixazomib The metabolism of Ixazomib can be decreased when combined with Diphenhydramine. Approved, Investigational Ketamine The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Ketamine. Approved, Vet Approved Ketazolam The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Ketazolam. Approved Ketobemidone The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Ketobemidone. Approved, Investigational Ketoconazole The metabolism of Diphenhydramine can be decreased when combined with Ketoconazole. Approved, Investigational Labetalol The metabolism of Labetalol can be decreased when combined with Diphenhydramine. Approved Lamotrigine The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Lamotrigine. Approved, Investigational Leflunomide The metabolism of Diphenhydramine can be decreased when combined with Leflunomide. Approved, Investigational Lenvatinib Diphenhydramine may increase the QTc-prolonging activities of Lenvatinib. Approved, Investigational Letermovir The metabolism of Letermovir can be decreased when combined with Diphenhydramine. Approved, Investigational Leuprolide Diphenhydramine may increase the QTc-prolonging activities of Leuprolide. Approved, Investigational Levetiracetam The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Levetiracetam. Approved, Investigational Levobupivacaine The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Levobupivacaine. Approved, Investigational Levocabastine The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Levocabastine. Approved, Investigational Levocetirizine The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Levocetirizine. Approved Levodopa The metabolism of Levodopa can be decreased when combined with Diphenhydramine. Approved Levofloxacin Diphenhydramine may increase the QTc-prolonging activities of Levofloxacin. Approved, Investigational Levomethadyl Acetate The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Levomethadyl Acetate. Approved, Investigational Levomilnacipran The metabolism of Levomilnacipran can be decreased when combined with Diphenhydramine. Approved, Investigational Levorphanol The risk or severity of adverse effects can be increased when Levorphanol is combined with Diphenhydramine. Approved Lidocaine The metabolism of Diphenhydramine can be decreased when combined with Lidocaine. Approved, Vet Approved Lisdexamfetamine Lisdexamfetamine may decrease the sedative activities of Diphenhydramine. Approved, Investigational Lisuride The metabolism of Lisuride can be decreased when combined with Diphenhydramine. Approved, Investigational Lithium The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Lithium. Approved Lobeglitazone The metabolism of Diphenhydramine can be decreased when combined with Lobeglitazone. Approved, Investigational Lofentanil The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Lofentanil. Illicit Lomustine The metabolism of Lomustine can be decreased when combined with Diphenhydramine. Approved, Investigational Loperamide The metabolism of Loperamide can be decreased when combined with Diphenhydramine. Approved Lopinavir The metabolism of Diphenhydramine can be decreased when combined with Lopinavir. Approved Loprazolam The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Loprazolam. Experimental Loratadine The metabolism of Loratadine can be decreased when combined with Diphenhydramine. Approved, Investigational Lorazepam The risk or severity of adverse effects can be increased when Lorazepam is combined with Diphenhydramine. Approved Lorcaserin The metabolism of Lorcaserin can be decreased when combined with Diphenhydramine. Approved Lormetazepam The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Lormetazepam. Approved Lorpiprazole The metabolism of Lorpiprazole can be decreased when combined with Diphenhydramine. Approved Losartan The metabolism of Diphenhydramine can be decreased when combined with Losartan. Approved Lovastatin The metabolism of Diphenhydramine can be decreased when combined with Lovastatin. Approved, Investigational Loxapine The risk or severity of adverse effects can be increased when Loxapine is combined with Diphenhydramine. Approved Luliconazole The serum concentration of Diphenhydramine can be increased when it is combined with Luliconazole. Approved Lumacaftor The serum concentration of Diphenhydramine can be decreased when it is combined with Lumacaftor. Approved Lumefantrine Diphenhydramine may increase the QTc-prolonging activities of Lumefantrine. Approved Lurasidone The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Lurasidone. Approved, Investigational Magnesium sulfate The therapeutic efficacy of Diphenhydramine can be increased when used in combination with Magnesium sulfate. Approved, Investigational, Vet Approved Manidipine The metabolism of Diphenhydramine can be decreased when combined with Manidipine. Approved, Investigational Maprotiline The metabolism of Maprotiline can be decreased when combined with Diphenhydramine. Approved, Investigational Mebicar The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Mebicar. Experimental Meclizine The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Meclizine. Approved Medazepam The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Medazepam. Experimental Medetomidine The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Medetomidine. Vet Approved Melatonin The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Melatonin. Approved, Nutraceutical, Vet Approved Melperone The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Melperone. Approved, Investigational Mephedrone Mephedrone may decrease the sedative activities of Diphenhydramine. Investigational Mephentermine Mephentermine may decrease the sedative activities of Diphenhydramine. Approved Mephenytoin The metabolism of Mephenytoin can be decreased when combined with Diphenhydramine. Investigational, Withdrawn Mepivacaine The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Mepivacaine. Approved, Vet Approved Meprobamate The risk or severity of adverse effects can be increased when Meprobamate is combined with Diphenhydramine. Approved, Illicit Meptazinol The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Meptazinol. Experimental Mequitazine The metabolism of Mequitazine can be decreased when combined with Diphenhydramine. Approved Mesoridazine The metabolism of Mesoridazine can be decreased when combined with Diphenhydramine. Approved, Investigational Metaxalone The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Metaxalone. Approved Methadone The metabolism of Methadone can be decreased when combined with Diphenhydramine. Approved Methadyl Acetate The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Methadyl Acetate. Approved, Illicit Methamphetamine The metabolism of Methamphetamine can be decreased when combined with Diphenhydramine. Approved, Illicit Methapyrilene The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Methapyrilene. Withdrawn Methaqualone The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Methaqualone. Illicit, Withdrawn Methocarbamol The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Methocarbamol. Approved, Vet Approved Methohexital The risk or severity of adverse effects can be increased when Methohexital is combined with Diphenhydramine. Approved Methotrimeprazine Diphenhydramine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. Approved, Investigational Methoxyflurane The metabolism of Methoxyflurane can be decreased when combined with Diphenhydramine. Approved, Investigational, Vet Approved Methoxyphenamine Methoxyphenamine may decrease the sedative activities of Diphenhydramine. Experimental Methsuximide The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Methsuximide. Approved Methylecgonine The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Methylecgonine. Experimental Methylphenidate The metabolism of Methylphenidate can be decreased when combined with Diphenhydramine. Approved, Investigational Methylphenobarbital The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Methylphenobarbital. Approved Methyprylon The metabolism of Methyprylon can be decreased when combined with Diphenhydramine. Approved, Illicit, Withdrawn Metoclopramide The metabolism of Metoclopramide can be decreased when combined with Diphenhydramine. Approved, Investigational Metoprolol The serum concentration of Metoprolol can be increased when it is combined with Diphenhydramine. Approved, Investigational Metyrosine Diphenhydramine may increase the sedative activities of Metyrosine. Approved Mexiletine The metabolism of Diphenhydramine can be decreased when combined with Mexiletine. Approved, Investigational Mianserin The metabolism of Mianserin can be decreased when combined with Diphenhydramine. Approved, Investigational Midazolam The risk or severity of adverse effects can be increased when Midazolam is combined with Diphenhydramine. Approved, Illicit Midomafetamine Midomafetamine may decrease the sedative activities of Diphenhydramine. Experimental, Illicit, Investigational Midostaurin The metabolism of Diphenhydramine can be decreased when combined with Midostaurin. Approved, Investigational Mifepristone The serum concentration of Diphenhydramine can be increased when it is combined with Mifepristone. Approved, Investigational Milnacipran The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Milnacipran. Approved, Investigational Minaprine The metabolism of Minaprine can be decreased when combined with Diphenhydramine. Approved Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Diphenhydramine. Approved, Investigational Mirabegron The metabolism of Mirabegron can be decreased when combined with Diphenhydramine. Approved Mirtazapine Diphenhydramine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. Approved MMDA MMDA may decrease the sedative activities of Diphenhydramine. Experimental, Illicit Moclobemide The metabolism of Moclobemide can be decreased when combined with Diphenhydramine. Approved, Investigational Modafinil The metabolism of Diphenhydramine can be decreased when combined with Modafinil. Approved, Investigational Molindone The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Molindone. Approved Morphine The metabolism of Morphine can be decreased when combined with Diphenhydramine. Approved, Investigational Moxifloxacin Diphenhydramine may increase the QTc-prolonging activities of Moxifloxacin. Approved, Investigational Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Diphenhydramine. Approved, Investigational Nalbuphine The risk or severity of adverse effects can be increased when Nalbuphine is combined with Diphenhydramine. Approved Nateglinide The metabolism of Nateglinide can be decreased when combined with Diphenhydramine. Approved, Investigational Nebivolol The serum concentration of Nebivolol can be increased when it is combined with Diphenhydramine. Approved, Investigational Nefazodone The metabolism of Nefazodone can be decreased when combined with Diphenhydramine. Approved, Withdrawn Nelfinavir The metabolism of Diphenhydramine can be decreased when combined with Nelfinavir. Approved Netupitant The metabolism of Netupitant can be decreased when combined with Diphenhydramine. Approved, Investigational Nevirapine The metabolism of Diphenhydramine can be increased when combined with Nevirapine. Approved Nicardipine The metabolism of Diphenhydramine can be decreased when combined with Nicardipine. Approved, Investigational Nicergoline The metabolism of Nicergoline can be decreased when combined with Diphenhydramine. Approved, Investigational Nicotine The metabolism of Nicotine can be decreased when combined with Diphenhydramine. Approved Nifedipine The metabolism of Nifedipine can be decreased when combined with Diphenhydramine. Approved Nilotinib Diphenhydramine may increase the QTc-prolonging activities of Nilotinib. Approved, Investigational Nitrazepam The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Nitrazepam. Approved Nitrofural The metabolism of Nitrofural can be decreased when combined with Diphenhydramine. Approved, Investigational, Vet Approved Nitrous oxide The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Nitrous oxide. Approved, Vet Approved Norflurane The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Norflurane. Approved, Investigational Normethadone The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Normethadone. Approved, Illicit Nortriptyline The metabolism of Nortriptyline can be decreased when combined with Diphenhydramine. Approved Ofloxacin Diphenhydramine may increase the QTc-prolonging activities of Ofloxacin. Approved Olanzapine The metabolism of Olanzapine can be decreased when combined with Diphenhydramine. Approved, Investigational Olopatadine The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Olopatadine. Approved Omeprazole The metabolism of Diphenhydramine can be decreased when combined with Omeprazole. Approved, Investigational, Vet Approved Ondansetron The metabolism of Ondansetron can be decreased when combined with Diphenhydramine. Approved Opium The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Opium. Approved, Illicit Orphenadrine Diphenhydramine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. Approved Osanetant The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Osanetant. Investigational Osimertinib The serum concentration of Diphenhydramine can be decreased when it is combined with Osimertinib. Approved Oxazepam The risk or severity of adverse effects can be increased when Oxazepam is combined with Diphenhydramine. Approved Oxethazaine The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Oxethazaine. Approved, Investigational Oxprenolol The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Oxprenolol. Approved Oxybuprocaine The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Oxybuprocaine. Approved, Investigational Oxycodone The metabolism of Oxycodone can be decreased when combined with Diphenhydramine. Approved, Illicit, Investigational Oxymorphone The metabolism of Oxymorphone can be decreased when combined with Diphenhydramine. Approved, Investigational, Vet Approved Paliperidone Diphenhydramine may increase the QTc-prolonging activities of Paliperidone. Approved Palonosetron The metabolism of Palonosetron can be decreased when combined with Diphenhydramine. Approved, Investigational Panobinostat The serum concentration of Diphenhydramine can be increased when it is combined with Panobinostat. Approved, Investigational Pantoprazole The metabolism of Diphenhydramine can be decreased when combined with Pantoprazole. Approved Paraldehyde Diphenhydramine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. Approved, Investigational Paroxetine The metabolism of Diphenhydramine can be decreased when combined with Paroxetine. Approved, Investigational Pazopanib The metabolism of Pazopanib can be decreased when combined with Diphenhydramine. Approved Peginterferon alfa-2b The serum concentration of Diphenhydramine can be decreased when it is combined with Peginterferon alfa-2b. Approved Penfluridol The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Penfluridol. Experimental Pentamidine The metabolism of Pentamidine can be decreased when combined with Diphenhydramine. Approved, Investigational Pentazocine The risk or severity of adverse effects can be increased when Pentazocine is combined with Diphenhydramine. Approved, Vet Approved Pentobarbital The risk or severity of adverse effects can be increased when Pentobarbital is combined with Diphenhydramine. Approved, Investigational, Vet Approved Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Diphenhydramine. Approved Perazine The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Perazine. Approved, Investigational Perflutren Diphenhydramine may increase the QTc-prolonging activities of Perflutren. Approved Perhexiline The metabolism of Perhexiline can be decreased when combined with Diphenhydramine. Approved, Investigational Perospirone The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Perospirone. Approved Perphenazine The metabolism of Perphenazine can be decreased when combined with Diphenhydramine. Approved Pethidine The metabolism of Pethidine can be decreased when combined with Diphenhydramine. Approved Phenacetin The metabolism of Phenacetin can be decreased when combined with Diphenhydramine. Withdrawn Phenazocine The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Phenazocine. Experimental Phenformin The metabolism of Phenformin can be decreased when combined with Diphenhydramine. Approved, Investigational, Withdrawn Phenibut The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Phenibut. Experimental Phenobarbital The metabolism of Diphenhydramine can be increased when combined with Phenobarbital. Approved, Investigational Phenoperidine The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Phenoperidine. Experimental Phenoxyethanol The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Phenoxyethanol. Approved Phentermine Phentermine may decrease the sedative activities of Diphenhydramine. Approved, Illicit Phenytoin The metabolism of Diphenhydramine can be increased when combined with Phenytoin. Approved, Vet Approved Pimozide Diphenhydramine may increase the QTc-prolonging activities of Pimozide. Approved Pindolol The metabolism of Pindolol can be decreased when combined with Diphenhydramine. Approved, Investigational Pipamperone The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Pipamperone. Approved, Investigational Piperazine The metabolism of Piperazine can be decreased when combined with Diphenhydramine. Approved, Vet Approved Pipotiazine The metabolism of Pipotiazine can be decreased when combined with Diphenhydramine. Approved, Investigational Piritramide The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Piritramide. Approved, Investigational Pitolisant The serum concentration of Pitolisant can be increased when it is combined with Diphenhydramine. Approved, Investigational Pizotifen The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Pizotifen. Approved Pomalidomide The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Pomalidomide. Approved Ponatinib The metabolism of Ponatinib can be decreased when combined with Diphenhydramine. Approved, Investigational Pramipexole Diphenhydramine may increase the sedative activities of Pramipexole. Approved, Investigational Pramocaine The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Pramocaine. Approved Prazepam The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Prazepam. Approved, Illicit Pregabalin The therapeutic efficacy of Diphenhydramine can be increased when used in combination with Pregabalin. Approved, Illicit, Investigational Prilocaine The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Prilocaine. Approved Primaquine Diphenhydramine may increase the QTc-prolonging activities of Primaquine. Approved Primidone The metabolism of Diphenhydramine can be increased when combined with Primidone. Approved, Vet Approved Procainamide Diphenhydramine may increase the QTc-prolonging activities of Procainamide. Approved Procaine The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Procaine. Approved, Investigational, Vet Approved Prochlorperazine The metabolism of Prochlorperazine can be decreased when combined with Diphenhydramine. Approved, Vet Approved Progesterone The metabolism of Progesterone can be decreased when combined with Diphenhydramine. Approved, Vet Approved Promazine The metabolism of Diphenhydramine can be decreased when combined with Promazine. Approved, Vet Approved Promethazine The metabolism of Promethazine can be decreased when combined with Diphenhydramine. Approved, Investigational Propafenone The serum concentration of Diphenhydramine can be increased when it is combined with Propafenone. Approved Propanidid The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Propanidid. Experimental Proparacaine The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Proparacaine. Approved, Vet Approved Propofol The metabolism of Propofol can be decreased when combined with Diphenhydramine. Approved, Investigational, Vet Approved Propoxycaine The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Propoxycaine. Approved Propranolol The metabolism of Propranolol can be decreased when combined with Diphenhydramine. Approved, Investigational Protriptyline The metabolism of Protriptyline can be decreased when combined with Diphenhydramine. Approved Proxibarbal The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Proxibarbal. Experimental PSD502 The risk or severity of adverse effects can be increased when Diphenhydramine is combined with PSD502. Investigational Pseudoephedrine The metabolism of Pseudoephedrine can be decreased when combined with Diphenhydramine. Approved Pyrimethamine The metabolism of Diphenhydramine can be decreased when combined with Pyrimethamine. Approved, Investigational, Vet Approved Quazepam The serum concentration of Diphenhydramine can be increased when it is combined with Quazepam. Approved, Illicit Quetiapine Diphenhydramine may increase the QTc-prolonging activities of Quetiapine. Approved Quinidine The metabolism of Diphenhydramine can be decreased when combined with Quinidine. Approved, Investigational Quinine Diphenhydramine may increase the QTc-prolonging activities of Quinine. Approved Quinisocaine The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Quinisocaine. Experimental Raclopride The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Raclopride. Investigational Ramelteon The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Ramelteon. Approved, Investigational Ranitidine The metabolism of Ranitidine can be decreased when combined with Diphenhydramine. Approved Ranolazine The metabolism of Diphenhydramine can be decreased when combined with Ranolazine. Approved, Investigational Remifentanil The risk or severity of adverse effects can be increased when Remifentanil is combined with Diphenhydramine. Approved Remoxipride The metabolism of Remoxipride can be decreased when combined with Diphenhydramine. Approved, Withdrawn Repinotan The metabolism of Repinotan can be decreased when combined with Diphenhydramine. Investigational Reserpine The risk or severity of adverse effects can be increased when Reserpine is combined with Diphenhydramine. Approved, Investigational Rifampicin The metabolism of Diphenhydramine can be increased when combined with Rifampicin. Approved Rifapentine The metabolism of Diphenhydramine can be increased when combined with Rifapentine. Approved, Investigational Risperidone The metabolism of Risperidone can be decreased when combined with Diphenhydramine. Approved, Investigational Ritanserin The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Ritanserin. Investigational Ritobegron Ritobegron may decrease the sedative activities of Diphenhydramine. Investigational Ritonavir The metabolism of Diphenhydramine can be decreased when combined with Ritonavir. Approved, Investigational Rolapitant The metabolism of Diphenhydramine can be decreased when combined with Rolapitant. Approved, Investigational Romifidine The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Romifidine. Vet Approved Ropinirole Diphenhydramine may increase the sedative activities of Ropinirole. Approved, Investigational Ropivacaine The metabolism of Ropivacaine can be decreased when combined with Diphenhydramine. Approved Rotigotine Diphenhydramine may increase the sedative activities of Rotigotine. Approved Rucaparib The metabolism of Rucaparib can be decreased when combined with Diphenhydramine. Approved, Investigational Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Diphenhydramine. Approved Rupatadine The metabolism of Rupatadine can be decreased when combined with Diphenhydramine. Approved Saquinavir The metabolism of Saquinavir can be decreased when combined with Diphenhydramine. Approved, Investigational Scopolamine The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Scopolamine. Approved, Investigational Secobarbital The metabolism of Diphenhydramine can be increased when combined with Secobarbital. Approved, Vet Approved Sepranolone The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Sepranolone. Investigational Sertindole The metabolism of Sertindole can be decreased when combined with Diphenhydramine. Approved, Investigational, Withdrawn Sertraline The metabolism of Sertraline can be decreased when combined with Diphenhydramine. Approved Sevoflurane The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Sevoflurane. Approved, Vet Approved Sildenafil The metabolism of Sildenafil can be decreased when combined with Diphenhydramine. Approved, Investigational Simeprevir The metabolism of Diphenhydramine can be decreased when combined with Simeprevir. Approved Simvastatin The metabolism of Simvastatin can be decreased when combined with Diphenhydramine. Approved Sodium oxybate Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Diphenhydramine. Approved Sorafenib The metabolism of Diphenhydramine can be decreased when combined with Sorafenib. Approved, Investigational Sotalol Diphenhydramine may increase the QTc-prolonging activities of Sotalol. Approved Sparteine The metabolism of Sparteine can be decreased when combined with Diphenhydramine. Experimental Stiripentol The metabolism of Diphenhydramine can be decreased when combined with Stiripentol. Approved Sufentanil The risk or severity of adverse effects can be increased when Sufentanil is combined with Diphenhydramine. Approved, Investigational Sulfadiazine The metabolism of Diphenhydramine can be decreased when combined with Sulfadiazine. Approved, Investigational, Vet Approved Sulfamethoxazole The metabolism of Diphenhydramine can be decreased when combined with Sulfamethoxazole. Approved Sulfisoxazole The metabolism of Diphenhydramine can be decreased when combined with Sulfisoxazole. Approved, Vet Approved Sulpiride The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Sulpiride. Approved, Investigational Sultopride The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Sultopride. Experimental Suvorexant Diphenhydramine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. Approved, Investigational Tamoxifen The serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Diphenhydramine resulting in a loss in efficacy. Approved Tamsulosin The metabolism of Tamsulosin can be decreased when combined with Diphenhydramine. Approved, Investigational Tandospirone The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Tandospirone. Investigational Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Diphenhydramine. Approved Tasimelteon The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Tasimelteon. Approved, Investigational Technetium Tc-99m tilmanocept Diphenhydramine may decrease effectiveness of Technetium Tc-99m tilmanocept as a diagnostic agent. Approved, Investigational Tegaserod The metabolism of Tegaserod can be decreased when combined with Diphenhydramine. Approved, Investigational, Withdrawn Telavancin Diphenhydramine may increase the QTc-prolonging activities of Telavancin. Approved Telithromycin Diphenhydramine may increase the QTc-prolonging activities of Telithromycin. Approved Temazepam The risk or severity of adverse effects can be increased when Temazepam is combined with Diphenhydramine. Approved, Investigational Tenofovir disoproxil The metabolism of Diphenhydramine can be decreased when combined with Tenofovir disoproxil. Approved, Investigational Terbinafine The metabolism of Diphenhydramine can be decreased when combined with Terbinafine. Approved, Investigational, Vet Approved Terfenadine The metabolism of Terfenadine can be decreased when combined with Diphenhydramine. Approved, Withdrawn Teriflunomide The serum concentration of Diphenhydramine can be decreased when it is combined with Teriflunomide. Approved Tesmilifene The metabolism of Tesmilifene can be decreased when combined with Diphenhydramine. Investigational Tetrabenazine Diphenhydramine may increase the QTc-prolonging activities of Tetrabenazine. Approved, Investigational Tetracaine The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Tetracaine. Approved, Vet Approved Tetrahydropalmatine The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Tetrahydropalmatine. Investigational Tetrodotoxin The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Tetrodotoxin. Investigational Thalidomide Diphenhydramine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. Approved, Investigational, Withdrawn Theophylline The metabolism of Diphenhydramine can be decreased when combined with Theophylline. Approved Thiamylal The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Thiamylal. Approved, Vet Approved Thiopental The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Thiopental. Approved, Vet Approved Thioridazine The serum concentration of Thioridazine can be increased when it is combined with Diphenhydramine. Approved, Withdrawn Thiotepa The metabolism of Diphenhydramine can be decreased when combined with Thiotepa. Approved, Investigational Thiothixene The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Thiothixene. Approved Tiagabine The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Tiagabine. Approved, Investigational Tiapride The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Tiapride. Approved, Investigational Ticagrelor The metabolism of Diphenhydramine can be decreased when combined with Ticagrelor. Approved Ticlopidine The metabolism of Diphenhydramine can be decreased when combined with Ticlopidine. Approved Tiletamine The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Tiletamine. Vet Approved Tilidine The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Tilidine. Experimental Timolol The metabolism of Timolol can be decreased when combined with Diphenhydramine. Approved Tiotropium The metabolism of Tiotropium can be decreased when combined with Diphenhydramine. Approved Tipranavir The metabolism of Diphenhydramine can be decreased when combined with Tipranavir. Approved, Investigational Tizanidine The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Tizanidine. Approved, Investigational Tolbutamide The metabolism of Diphenhydramine can be decreased when combined with Tolbutamide. Approved, Investigational Tolcapone The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Tolcapone. Approved, Withdrawn Tolterodine The metabolism of Tolterodine can be decreased when combined with Diphenhydramine. Approved, Investigational Topiramate The metabolism of Diphenhydramine can be decreased when combined with Topiramate. Approved Topiroxostat The metabolism of Diphenhydramine can be decreased when combined with Topiroxostat. Approved, Investigational Toremifene Diphenhydramine may increase the QTc-prolonging activities of Toremifene. Approved, Investigational Trabectedin The metabolism of Trabectedin can be decreased when combined with Diphenhydramine. Approved, Investigational Tramadol The therapeutic efficacy of Tramadol can be decreased when used in combination with Diphenhydramine. Approved, Investigational Tranylcypromine The metabolism of Diphenhydramine can be decreased when combined with Tranylcypromine. Approved, Investigational Trazodone The metabolism of Trazodone can be decreased when combined with Diphenhydramine. Approved, Investigational Triazolam The risk or severity of adverse effects can be increased when Triazolam is combined with Diphenhydramine. Approved, Investigational Tricaine methanesulfonate The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Tricaine methanesulfonate. Vet Approved Trichloroethylene The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Trichloroethylene. Approved Trifluoperazine The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Diphenhydramine. Approved, Investigational Trifluperidol The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Trifluperidol. Experimental Triflupromazine The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Triflupromazine. Approved, Vet Approved Trimethoprim The metabolism of Diphenhydramine can be decreased when combined with Trimethoprim. Approved, Vet Approved Trimipramine The metabolism of Trimipramine can be decreased when combined with Diphenhydramine. Approved Triprolidine The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Triprolidine. Approved Umeclidinium The metabolism of Umeclidinium can be decreased when combined with Diphenhydramine. Approved Valbenazine The metabolism of Valbenazine can be decreased when combined with Diphenhydramine. Approved, Investigational Valproic Acid The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Valproic Acid. Approved, Investigational Valsartan The metabolism of Diphenhydramine can be decreased when combined with Valsartan. Approved, Investigational Vandetanib Diphenhydramine may increase the QTc-prolonging activities of Vandetanib. Approved Vemurafenib The serum concentration of Diphenhydramine can be increased when it is combined with Vemurafenib. Approved Venlafaxine The metabolism of Diphenhydramine can be decreased when combined with Venlafaxine. Approved Veralipride The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Veralipride. Experimental Vernakalant The metabolism of Vernakalant can be decreased when combined with Diphenhydramine. Approved, Investigational Vigabatrin The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Vigabatrin. Approved Vilazodone The metabolism of Vilazodone can be decreased when combined with Diphenhydramine. Approved Vinblastine The metabolism of Vinblastine can be decreased when combined with Diphenhydramine. Approved Vinorelbine The metabolism of Vinorelbine can be decreased when combined with Diphenhydramine. Approved, Investigational Vinyl ether The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Vinyl ether. Experimental Voriconazole The metabolism of Diphenhydramine can be decreased when combined with Voriconazole. Approved, Investigational Vortioxetine The metabolism of Vortioxetine can be decreased when combined with Diphenhydramine. Approved, Investigational Xenon The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Xenon. Experimental Xylazine The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Xylazine. Vet Approved Yohimbine The metabolism of Yohimbine can be decreased when combined with Diphenhydramine. Approved, Investigational, Vet Approved Zafirlukast The metabolism of Diphenhydramine can be decreased when combined with Zafirlukast. Approved, Investigational Zalcitabine The metabolism of Zalcitabine can be decreased when combined with Diphenhydramine. Approved, Investigational Zaleplon The risk or severity of adverse effects can be increased when Zaleplon is combined with Diphenhydramine. Approved, Illicit, Investigational Ziconotide The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Ziconotide. Approved Zimelidine The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Zimelidine. Withdrawn Ziprasidone Diphenhydramine may increase the QTc-prolonging activities of Ziprasidone. Approved Zolazepam The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Zolazepam. Vet Approved Zolpidem Diphenhydramine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. Approved Zonisamide The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Zonisamide. Approved, Investigational Zopiclone The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Zopiclone. Approved Zotepine The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Zotepine. Approved, Investigational, Withdrawn Zucapsaicin The metabolism of Diphenhydramine can be decreased when combined with Zucapsaicin. Approved, Investigational Zuclopenthixol Diphenhydramine may increase the QTc-prolonging activities of Zuclopenthixol. Approved, Investigational - Food Interactions
- Avoid alcohol.
- Take with food.
References
- Synthesis Reference
Alison B. Lukacsko, Joseph J. Piala, "Effect of a combination of a terbutaline, diphenhydramine and ranitidine composition on gastrointestinal injury produced by nonsteroidal anti-inflammatory compositions." U.S. Patent US5260333, issued December, 1983.
US5260333- General References
- Raphael GD, Angello JT, Wu MM, Druce HM: Efficacy of diphenhydramine vs desloratadine and placebo in patients with moderate-to-severe seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 2006 Apr;96(4):606-14. [PubMed:16680933]
- Abdi A, Rose E, Levine M: Diphenhydramine overdose with intraventricular conduction delay treated with hypertonic sodium bicarbonate and i.v. lipid emulsion. West J Emerg Med. 2014 Nov;15(7):855-8. doi: 10.5811/westjem.2014.8.23407. Epub 2014 Sep 19. [PubMed:25493135]
- External Links
- Human Metabolome Database
- HMDB0001927
- KEGG Drug
- D00300
- KEGG Compound
- C06960
- PubChem Compound
- 3100
- PubChem Substance
- 46505484
- ChemSpider
- 2989
- BindingDB
- 50017674
- ChEBI
- 4636
- ChEMBL
- CHEMBL657
- Therapeutic Targets Database
- DAP000490
- PharmGKB
- PA449349
- IUPHAR
- 1224
- Guide to Pharmacology
- GtP Drug Page
- HET
- 2PM
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Diphenhydramine
- ATC Codes
- D04AA32 — Diphenhydramine
- D04AA — Antihistamines for topical use
- D04A — ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.
- D04 — ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.
- D — DERMATOLOGICALS
- D04AA — Antihistamines for topical use
- D04A — ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.
- D04 — ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.
- D — DERMATOLOGICALS
- R06AA — Aminoalkyl ethers
- R06A — ANTIHISTAMINES FOR SYSTEMIC USE
- R06 — ANTIHISTAMINES FOR SYSTEMIC USE
- R — RESPIRATORY SYSTEM
- AHFS Codes
- 04:04.04 — Ethanolamine Derivatives
- 04:04.00 — First Generation Antihistamines
- PDB Entries
- 2aot
- MSDS
- Download (73.5 KB)
Clinical Trials
- Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Advance Pharmaceutical
- Advent Pharmaceuticals Inc.
- Amend
- APP Pharmaceuticals
- A-S Medication Solutions LLC
- Auriga Pharmaceuticals LLC
- Barr Pharmaceuticals
- Baxter International Inc.
- Bergen Brunswig
- Bioniche Pharma
- Bryant Ranch Prepack
- C.O. Truxton Inc.
- Cardinal Health
- Carlisle Laboratories Inc.
- Chattem Chemicals Inc.
- Concord Labs
- Consolidated Midland Corp.
- Contract Pharm
- CVS Pharmacy
- Darby Dental Supply Co. Inc.
- Dept Health Central Pharmacy
- Direct Dispensing Inc.
- DispenseXpress Inc.
- Dispensing Solutions
- Diversified Healthcare Services Inc.
- Eon Labs
- Equaline Vitamins
- Fusion Pharmaceuticals LLC
- General Injectables and Vaccines Inc.
- GlaxoSmithKline Inc.
- Goldline Laboratories Inc.
- Group Health Cooperative
- Hawthorn Pharmaceuticals
- Heartland Repack Services LLC
- Hospira Inc.
- Innoviant Pharmacy Inc.
- Ivax Pharmaceuticals
- Kraft Pharmaceutical Co. Inc.
- Liberty Pharmaceuticals
- Lnk International Inc.
- Major Pharmaceuticals
- Martin Surgical Supply
- McNeil Laboratories
- Medique Products
- Medtech Labs
- Merit Pharmaceuticals
- Midlothian Labs
- Mississippi State Dept Health
- Murfreesboro Pharmaceutical Nursing Supply
- Nexgen Pharma Inc.
- North Safety Products
- Nucare Pharmaceuticals Inc.
- Patient First Corp.
- PCA LLC
- PD-Rx Pharmaceuticals Inc.
- Perrigo Co.
- Pfizer Inc.
- Pharmaceutical Association
- Pharmedix
- Physicians Total Care Inc.
- Poly Pharmaceuticals Inc.
- Preferred Pharmaceuticals Inc.
- Prepackage Specialists
- Prepak Systems Inc.
- Prescript Pharmaceuticals
- Procter & Gamble
- Provident Pharmaceuticals LLC
- Remedy Repack
- Rite Aid Corp.
- River's Edge Pharmaceuticals
- Rugby Laboratories
- Sandhills Packaging Inc.
- Scientific Laboratories Inc.
- Silarx Pharmaceuticals
- Southwood Pharmaceuticals
- St Mary's Medical Park Pharmacy
- Tya Pharmaceuticals
- UDL Laboratories
- United Research Laboratories Inc.
- Vangard Labs Inc.
- Walgreen Co.
- Dosage forms
Form Route Strength Capsule; kit Oral Cream Topical 20 mg/mL Cream Topical 2 mL/100mL Powder Oral 25 mg/1 Liquid Oral 12.5 mg Tablet, chewable Oral 12.5 mg/1 Tablet, film coated Oral 25 mg/1 Solution Oral 12.5 mg Gel Topical 2 g/100g Cream Topical 2.0 % Patch Topical Kit Tablet Oral 25 mg Tablet, coated Oral 25 mg/1 Tablet, chewable Oral 12.5 mg Liquid Topical Liquid Oral 6.25 mg Cream Topical 2 % Elixir Oral 12.5 mg Gel Topical 20 mg/mL Tablet, chewable Oral 25 mg Gel Topical 2 % Tablet Oral 25 mg/250mg Strip Oral 25 mg Lotion Topical Suspension Topical Syrup Oral 6.25 mg Tablet Oral 19 mg Strip Oral 19 mg Suspension Oral Tablet Oral 12.5 mg/1 Liquid Oral 12.5 mg/5mL Kit; tablet Oral Ointment Topical Kit Topical Kit Oral Tablet Oral 38.0 mg Capsule, coated Oral 25 mg/1 Injection, solution Intravenous 50 mg/mL Capsule, liquid filled Oral 20 mg/1 Capsule, gelatin coated Oral 25 mg/1 Liquid Intravenous 50 mg Elixir Oral 12.5 mg/5mL Elixir Oral 25 mg/10mL Injection Intramuscular 50 mg/mL Injection Intramuscular; Intravenous 50 mg/mL Injection, solution Intramuscular; Intravenous 50 mg/mL Solution Oral 25 mg/10mL Solution Oral 50 mg/20mL Liquid Intramuscular; Intravenous 50 mg Kit Oral; Topical Tablet Oral Tablet, film coated Oral Liquid Oral 50 mg/30mL Solution Oral 50 mg/40mL Kit Oral Aerosol, spray Topical Capsule, coated Oral Tablet, coated Oral Powder Oral Capsule, liquid filled Oral Liquid Topical 20.3 g/L Spray Topical 2 g/100mL Aerosol Topical Solution Topical Gel Topical 2 g/100mL Strip Oral 12.5 mg Tablet Oral 12.5 mg Tablet, orally disintegrating Oral 12.5 mg/1 Liniment Topical Cream Topical Capsule, gelatin coated Oral 50 mg/1 Kit Lozenge Oral 25 mg Strip Oral Tablet Oral 50 mg/1 Capsule Oral 25 mg Solution Oral 50 mg Capsule Oral 50 mg/1 Tablet, film coated Oral 50 mg/1 Capsule, liquid filled Oral 50 mg/21 Solution Oral Tablet Oral 50 mg Capsule Oral Capsule, gelatin coated Oral Elixir Oral 2.5 mg Syrup Oral 12.5 mg/5mL Gel Topical 20.5 mg/mL Spray Topical Liquid Oral Plaster Topical Solution Intramuscular; Intravenous 50 mg Gel Topical .2 g/10mL Capsule, liquid filled Oral 50 mg/1 Capsule, liquid filled Oral 25 mg/1 Tablet Oral 25 mg/1 Tablet, coated Oral 50 mg/1 Gel Topical Gel Topical 20 mg/g Spray Topical 20 mg/mL Powder, for solution Oral Syrup Oral Capsule Oral 25 mg/1 Solution Oral 50 mg/30mL Capsule Oral 50 mg Tablet, chewable Oral 25 mg/1 Liquid Oral 6.25 mg/mL Solution Oral 12.5 mg/5mL Liquid Oral 25 mg/10mL Capsule, gelatin coated Oral 50 mg/21 Granule, for solution Oral Spray Topical 2.0 % Liquid Oral 50 mg - Prices
Unit description Cost Unit DiphenhydrAMINE HCl 100 50 mg capsule Bottle 13.99USD bottle Diphenhydramine 50 mg/ml 3.94USD ml Diphenhydramine 50 mg/ml vial 1.69USD ml DiphenhydrAMINE HCl 50 mg/ml vial 1.44USD vial Dytan 25 mg tablet chewable 1.37USD tablet Benadryl 50 mg/ml vial 1.36USD ml Diphenmax 25 mg tablet 1.24USD tablet Benadryl allergy 25 mg strips 0.45USD strip Unisom sleep aid tablet 0.34USD tablet Sleep-eze 3 tablet 0.29USD tablet Compoz 50 mg tablet 0.27USD tablet Sominex max str 50 mg caplet 0.27USD caplet Benadryl allergy fastmelt tablet 0.26USD tablet Unisom 25 mg sleeptabs 0.25USD tablet Unisom 50 mg sleepgels 0.25USD each Unisom sleepmelts 25 mg tablet 0.24USD tablet Nytol 25 mg tablet 0.23USD tablet Benadryl allergy-sinus caplet 0.22USD caplet Compoz 25 mg gelcap 0.2USD capsule Benadryl allergy 25 mg softgel 0.19USD softgel capsule Benadryl allergy 25 mg ultratab 0.19USD tablet Benadryl allergy-cold kapgels 0.19USD each Benadryl allergy-sinus kapgels 0.19USD each Benadryl-d allergy-sinus ultratab 0.19USD tablet Diphenhydramine hcl powder 0.17USD g Eql allergy 25 mg tablet 0.17USD tablet Nighttime sleep aid 25 mg cplt 0.17USD caplet Banophen anti-itch 2% cream 0.16USD g Benadryl itch relief stick 0.16USD ml Sominex 25 mg tablet 0.16USD tablet Benadryl allergy 25 mg kapgels 0.15USD each Allergy 25 mg tablet 0.14USD tablet Benadryl 25 mg kapseals 0.14USD each Benadryl itch stopping crm 0.14USD g DiphenhydrAMINE HCl 25 mg capsule 0.13USD capsule Diphenhist with zinc cream 0.12USD g Ra allergy 25 mg tablet 0.12USD tablet CVS Pharmacy allergy 25 mg tablet 0.11USD tablet Diphenhydramine 25 mg minitab 0.11USD tablet Simply sleep 25 mg caplet 0.11USD caplet Sleep ii tablet 0.11USD tablet Diphenhydramine 50 mg capsule 0.1USD capsule Benadryl 2% spray 0.09USD ml Diphenhist 50 mg tablet 0.09USD tablet Genahist 25 mg tablet 0.09USD tablet Ra sleep tablet 0.09USD tablet Banophen 25 mg tablet 0.08USD tablet Wal-dryl anti-itch spray 0.08USD ml CVS Pharmacy allergy 25 mg caplet 0.07USD caplet Nighttime sleep aid 25 mg caplet 0.07USD caplet CVS Pharmacy itch relief spray 0.06USD ml Diphen 25 mg capsule 0.06USD capsule Diphenhist 25 mg caplet 0.06USD caplet Benadryl anti-itch 0.45% gel 0.05USD g Diphenhydramine 50 mg caplet 0.05USD caplet Benadryl itch stopping gel 0.04USD g Child benadryl-d aller-sin liquid 0.04USD ml Diphenhydramine 25 mg capsule 0.04USD capsule Vicks 44d cough & head liquid 0.03USD ml Vicks 44e cough & chest liquid 0.03USD ml Banophen allergy liquid 0.02USD ml Diphenhydramine 25 mg tablet 0.02USD tablet Ra anti-tussive dm syrup 0.02USD ml Siladryl 12.5 mg/5 ml liquid 0.02USD ml Silphen cough syrup 0.02USD ml Silphen dm cough syrup 0.02USD ml DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
Patent Number Pediatric Extension Approved Expires (estimated) US8883849 No 2002-01-17 2022-01-17 US US9155718 No 2002-01-17 2022-01-17 US US8263647 No 2002-05-30 2022-05-30 US
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 161-162 Martin, H., Hafliger, F.,Gatzi, K.and Grob, A.; U.S. Patent 2,397,799; April 2,1946; assigned to J.R. Geigy AG, Switzerland. Rieveschl, G. Jr.; U.S. Patent 2,421,714; June 3,1947; assigned to Parke, Davis & Co. Rieveschl, G. Jr.; U.S. Patent 2,427,878; September 23,1947; assigned to Parke, Davis & Company. boiling point (°C) 150-165 °C at 2.00E+00 mm Hg PhysProp water solubility 3060 mg/L (at 37 °C) BEILSTEIN logP 3.27 HANSCH,C ET AL. (1995) pKa 8.98 SANGSTER (1994) - Predicted Properties
Property Value Source Water Solubility 0.0752 mg/mL ALOGPS logP 3.44 ALOGPS logP 3.65 ChemAxon logS -3.5 ALOGPS pKa (Strongest Basic) 8.87 ChemAxon Physiological Charge 1 ChemAxon Hydrogen Acceptor Count 2 ChemAxon Hydrogen Donor Count 0 ChemAxon Polar Surface Area 12.47 Å2 ChemAxon Rotatable Bond Count 6 ChemAxon Refractivity 79.93 m3·mol-1 ChemAxon Polarizability 29.86 Å3 ChemAxon Number of Rings 2 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule Yes ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
Property Value Probability Human Intestinal Absorption + 0.9898 Blood Brain Barrier + 0.9381 Caco-2 permeable + 0.8744 P-glycoprotein substrate Substrate 0.6211 P-glycoprotein inhibitor I Non-inhibitor 0.6632 P-glycoprotein inhibitor II Non-inhibitor 0.8381 Renal organic cation transporter Inhibitor 0.7752 CYP450 2C9 substrate Non-substrate 0.7897 CYP450 2D6 substrate Substrate 0.8919 CYP450 3A4 substrate Substrate 0.6173 CYP450 1A2 substrate Inhibitor 0.8306 CYP450 2C9 inhibitor Non-inhibitor 0.9144 CYP450 2D6 inhibitor Inhibitor 0.8932 CYP450 2C19 inhibitor Non-inhibitor 0.9039 CYP450 3A4 inhibitor Non-inhibitor 0.934 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.7293 Ames test Non AMES toxic 0.9132 Carcinogenicity Non-carcinogens 0.6495 Biodegradation Not ready biodegradable 0.9253 Rat acute toxicity 2.7846 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.536 hERG inhibition (predictor II) Inhibitor 0.6318
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Benzene and substituted derivatives
- Sub Class
- Diphenylmethanes
- Direct Parent
- Diphenylmethanes
- Alternative Parents
- Benzylethers / Trialkylamines / Dialkyl ethers / Organopnictogen compounds / Hydrocarbon derivatives
- Substituents
- Diphenylmethane / Benzylether / Tertiary aliphatic amine / Tertiary amine / Ether / Dialkyl ether / Organic nitrogen compound / Organic oxygen compound / Organopnictogen compound / Hydrocarbon derivative
- Molecular Framework
- Aromatic homomonocyclic compounds
- External Descriptors
- tertiary amino compound, ether (CHEBI:4636) / a small molecule (CPD-10890)
Targets
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Antagonist
- General Function
- Histamine receptor activity
- Specific Function
- In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamin...
- Gene Name
- HRH1
- Uniprot ID
- P35367
- Uniprot Name
- Histamine H1 receptor
- Molecular Weight
- 55783.61 Da
References
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
- Piao H, Nagai S, Tsurumaki T, Niki T, Higuchi H: Potentiation by neuropeptide Y of histamine H1 receptor-mediated contraction in rat blood vessels. Vascul Pharmacol. 2007 Apr;46(4):260-70. Epub 2006 Oct 27. [PubMed:17169617]
- Kesiova M, Alexandrova A, Yordanova N, Kirkova M, Todorov S: Effects of diphenhydramine and famotidine on lipid peroxidation and activities of antioxidant enzymes in different rat tissues. Pharmacol Rep. 2006 Mar-Apr;58(2):221-8. [PubMed:16702624]
- Hasala H, Moilanen E, Janka-Junttila M, Giembycz MA, Kankaanranta H: First-generation antihistamines diphenhydramine and chlorpheniramine reverse cytokine-afforded eosinophil survival by enhancing apoptosis. Allergy Asthma Proc. 2007 Jan-Feb;28(1):79-86. [PubMed:17390763]
- Wang Z, Woolverton WL: Self-administration of cocaine-antihistamine combinations: super-additive reinforcing effects. Eur J Pharmacol. 2007 Feb 28;557(2-3):159-60. Epub 2006 Dec 1. [PubMed:17196194]
- Ishikawa T, Takechi K, Rahman A, Ago J, Matsumoto N, Murakami A, Kamei C: Influences of histamine H1 receptor antagonists on maximal electroshock seizure in infant rats. Biol Pharm Bull. 2007 Mar;30(3):477-80. [PubMed:17329841]
- Havas TE, Cole P, Parker L, Oprysk D, Ayiomamitis A: The effects of combined H1 and H2 histamine antagonists on alterations in nasal airflow resistance induced by topical histamine provocation. J Allergy Clin Immunol. 1986 Nov;78(5 Pt 1):856-60. [PubMed:2878016]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Antagonist
- General Function
- G-protein coupled acetylcholine receptor activity
- Specific Function
- The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
- Gene Name
- CHRM2
- Uniprot ID
- P08172
- Uniprot Name
- Muscarinic acetylcholine receptor M2
- Molecular Weight
- 51714.605 Da
References
- Liu H, Zheng Q, Farley JM: Antimuscarinic actions of antihistamines on the heart. J Biomed Sci. 2006 May;13(3):395-401. [PubMed:16453179]
Enzymes
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- SubstrateInhibitor
- General Function
- Steroid hydroxylase activity
- Specific Function
- Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
- Gene Name
- CYP2D6
- Uniprot ID
- P10635
- Uniprot Name
- Cytochrome P450 2D6
- Molecular Weight
- 55768.94 Da
References
- Hamelin BA, Bouayad A, Drolet B, Gravel A, Turgeon J: In vitro characterization of cytochrome P450 2D6 inhibition by classic histamine H1 receptor antagonists. Drug Metab Dispos. 1998 Jun;26(6):536-9. [PubMed:9616188]
- Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
- Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP1A2
- Uniprot ID
- P05177
- Uniprot Name
- Cytochrome P450 1A2
- Molecular Weight
- 58293.76 Da
References
- Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Steroid hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP2C9
- Uniprot ID
- P11712
- Uniprot Name
- Cytochrome P450 2C9
- Molecular Weight
- 55627.365 Da
References
- Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Steroid hydroxylase activity
- Specific Function
- Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
- Gene Name
- CYP2C19
- Uniprot ID
- P33261
- Uniprot Name
- Cytochrome P450 2C19
- Molecular Weight
- 55930.545 Da
References
- Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Steroid hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP2C18
- Uniprot ID
- P33260
- Uniprot Name
- Cytochrome P450 2C18
- Molecular Weight
- 55710.075 Da
References
- Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Steroid hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP2B6
- Uniprot ID
- P20813
- Uniprot Name
- Cytochrome P450 2B6
- Molecular Weight
- 56277.81 Da
References
- Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Prostaglandin-endoperoxide synthase activity
- Specific Function
- Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gas...
- Gene Name
- PTGS1
- Uniprot ID
- P23219
- Uniprot Name
- Prostaglandin G/H synthase 1
- Molecular Weight
- 68685.82 Da
References
- Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
Transporters
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Quaternary ammonium group transmembrane transporter activity
- Specific Function
- Mediates tubular uptake of organic compounds from circulation. Mediates the influx of agmatine, dopamine, noradrenaline (norepinephrine), serotonin, choline, famotidine, ranitidine, histamin, creat...
- Gene Name
- SLC22A2
- Uniprot ID
- O15244
- Uniprot Name
- Solute carrier family 22 member 2
- Molecular Weight
- 62579.99 Da
References
- Urakami Y, Okuda M, Masuda S, Akazawa M, Saito H, Inui K: Distinct characteristics of organic cation transporters, OCT1 and OCT2, in the basolateral membrane of renal tubules. Pharm Res. 2001 Nov;18(11):1528-34. [PubMed:11758759]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Secondary active organic cation transmembrane transporter activity
- Specific Function
- Translocates a broad array of organic cations with various structures and molecular weights including the model compounds 1-methyl-4-phenylpyridinium (MPP), tetraethylammonium (TEA), N-1-methylnico...
- Gene Name
- SLC22A1
- Uniprot ID
- O15245
- Uniprot Name
- Solute carrier family 22 member 1
- Molecular Weight
- 61153.345 Da
References
- Urakami Y, Okuda M, Masuda S, Akazawa M, Saito H, Inui K: Distinct characteristics of organic cation transporters, OCT1 and OCT2, in the basolateral membrane of renal tubules. Pharm Res. 2001 Nov;18(11):1528-34. [PubMed:11758759]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Symporter activity
- Specific Function
- Sodium-ion dependent, high affinity carnitine transporter. Involved in the active cellular uptake of carnitine. Transports one sodium ion with one molecule of carnitine. Also transports organic cat...
- Gene Name
- SLC22A5
- Uniprot ID
- O76082
- Uniprot Name
- Solute carrier family 22 member 5
- Molecular Weight
- 62751.08 Da
References
- Ohashi R, Tamai I, Nezu Ji J, Nikaido H, Hashimoto N, Oku A, Sai Y, Shimane M, Tsuji A: Molecular and physiological evidence for multifunctionality of carnitine/organic cation transporter OCTN2. Mol Pharmacol. 2001 Feb;59(2):358-66. [PubMed:11160873]
Drug created on June 13, 2005 07:24 / Updated on April 23, 2018 23:06